Youngsoo Kim
CEO
Korean medicine doctor, PhD. Former principal investigator of a herbal medicine AI platform; an expert in Korean medicine data, AI and policy who leads technology development.
About JRP Bio
JRP stands for “Journey from Research to People.” Our name carries the whole journey from a discovery in the lab to the people it reaches.
Our name
Journey
Spec → evidence → approval, all the way through
Research
Starting from Korean medicine formulas and natural products
People
Finished as products people actually use
JRP Bio standardizes Korean medicine formulas and natural products, builds the evidence behind them, and secures approval to turn them into products people actually use. JRP Bio is the business brand of Jaein R&P Co., Ltd.
At a glance
Vision
From a discovery in the lab to the people it serves
Korean medicine and natural products carry a long history of use, but experience without specifications and evidence cannot leave the clinic, let alone the country. JRP Bio takes responsibility for the whole journey from research to people.
Mission
Turn Korean medicine formulas and natural materials into specifications that reproduce the same quality.
Demonstrate efficacy and safety with preclinical, clinical and real-world data.
Secure the right approval and launch it as a prescription drug, OTC drug, functional ingredient or overseas product.
Principles
We claim only what the evidence supports and say so when evidence is missing. We disclose specifications, data and approval stages as they are.
We don't call it a product until it can be made again to the same specification and gives the same result again. We work with a scientific attitude that never compromises on reproducibility.
We research and validate with a network of universities, hospitals, Korean medicine clinics, pharmaceutical and food companies. Only what is used in real care and real markets is a finished product.
Philosophy
在仁救民
Jae-in Gu-min
Abide in benevolence, and save people.
The 仁 in 在仁 (jae-in) is not 人 (person) but 仁 (benevolence). It means never leaving a place where a benevolent heart comes before profit or results; 救民 (gu-min) means that heart must go on to actually save people.
It stands on the tradition of calling medicine 仁術, the art of benevolence, and on the spirit of Dongui Bogam, compiled on the principles of practicality, nurturing life and care for the people.
Leadership
Youngsoo Kim
CEO
Korean medicine doctor, PhD. Former principal investigator of a herbal medicine AI platform; an expert in Korean medicine data, AI and policy who leads technology development.
Partners
Hanpoong Pharm (botanical drug commercialization MOU, 2022) · Huontech (food ingredient contract manufacturing)
Kyung Hee University Industry-Academic Cooperation Foundation · Kyung Hee University MRC
Kwangdong Pharmaceutical, Natural Product Convergence R&D Division (three-party MOU, 2024)
Sun Ten Pharmaceutical (Taiwan; joint R&D MOU, 2023)
Pre-A investors (two venture capital firms) · TIPS operator
History
Jecheon Production Center opening (planned)Planned
SH003 immune-enhancement patent granted
SH003 + docetaxel phase 2a IND approved (NSCLC)
SH003 immune function human study completed
Three-party MOU with Kwangdong Pharmaceutical and Kyung Hee University MRC
SH003 + docetaxel phase 1 completed
Minister of SMEs and Startups Award
Selected as an International Science Business Belt support company
Selected for TIPS
Joint R&D MOU with Sun Ten Pharmaceutical (Taiwan)
Botanical drug commercialization MOU with Hanpoong Pharm
SH003 high-dose phase 1 completed
Moved into Seoul Bio Hub · selected for Seoul Hongneung Innopolis H-Train and Bridge programs
Pre-A funding (KRW 2.4 billion cumulative)
SH003 high-dose phase 1 IND approved
SH003 US patent granted
SH003 monotherapy phase 2 IND approved (NSCLC)
SH003 monotherapy phase 1 completed (solid tumors)
SH003 Korean and international patents obtained
Jaein R&P Co., Ltd. founded